Federated Hermes Inc. Sells 852,375 Shares of Sanofi $SNY

Federated Hermes Inc. lessened its holdings in Sanofi (NASDAQ:SNY) by 21.9% during the third quarter, HoldingsChannel reports. The firm owned 3,035,254 shares of the company’s stock after selling 852,375 shares during the quarter. Federated Hermes Inc.’s holdings in Sanofi were worth $143,264,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. HM Payson & Co. lifted its position in shares of Sanofi by 3.4% during the 3rd quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after buying an additional 235 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its stake in Sanofi by 4.7% during the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock worth $252,000 after acquiring an additional 238 shares in the last quarter. CreativeOne Wealth LLC boosted its stake in shares of Sanofi by 2.8% in the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock valued at $434,000 after purchasing an additional 241 shares in the last quarter. Whipplewood Advisors LLC boosted its stake in shares of Sanofi by 18.2% in the 2nd quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after purchasing an additional 247 shares in the last quarter. Finally, Cetera Trust Company N.A grew its holdings in shares of Sanofi by 4.2% during the 2nd quarter. Cetera Trust Company N.A now owns 6,140 shares of the company’s stock valued at $297,000 after purchasing an additional 250 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on SNY shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and an average price target of $62.67.

Sanofi Stock Up 0.3%

Shares of NASDAQ:SNY opened at $47.49 on Wednesday. The firm has a market cap of $115.83 billion, a P/E ratio of 11.12, a P/E/G ratio of 1.37 and a beta of 0.45. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The business has a fifty day simple moving average of $48.31 and a 200 day simple moving average of $48.74. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.